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Abstract
Background:We investigated if new vessel formation in fat involves the contribution of local tissue-derived endothelial cells
(i.e., angiogenesis) or bone marrow-derived cells (BMDCs, i.e. vasculogenesis) and if antiangiogenic treatment by blockade
of vascular endothelial growth factor (VEGF) receptors can prevent diet-induced obesity (DIO).
Methodology/Principal Findings: We performed restorative bone marrow transplantation into wild-type mice using
transgenic mice expressing green fluorescent protein (GFP) constitutively (driven by b-actin promoter) or selectively in
endothelial cells (under Tie2 promoter activation) as donors. The presence of donor BMDCs in recipient mice was
investigated in fat tissue vessels after DIO using in vivo and ex vivo fluorescence microscopy. We investigated the roles of
VEGF receptors 1 and 2 (VEGFR1/VEGFR2) by inducing DIO in mice and treating them with blocking monoclonal antibodies.
We found only marginal (less than 1%) incorporation of BMDCs in fat vessels during DIO. When angiogenesis was inhibited
by blocking VEGFR2 in mice with DIO, treated mice had significantly lower body weights than control animals. In contrast,
blocking VEGFR1 had no discernable effect on the weight gain during DIO.
Conclusions/Significance: Formation of new vessels in fat tissues during DIO is largely due to angiogenesis rather than de
novo vasculogenesis. Antiangiogenic treatment by blockade of VEGFR2 but not VEGFR1 may limit adipose tissue expansion.
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Introduction
Adipose tissue is one of the most highly vascularized tissues in
the body, and a close functional relationship exists between fat
tissue and its vasculature [1]. Adipose tissue is well-known for its
angiogenic capacity, and has been used clinically to promote
wound healing and revascularization [1,2,3]. It remains
unknown if new vessel formation in fat requires blood circulating
progenitors, such as bone marrow-derived cells (BMDCs, a
process known as vasculogenesis). Vascular endothelial growth
factor-A (VEGF-A or VEGF) is believed to be responsible for
most of adipose tissue’s angiogenic capacity [4], and adipogen-
esis is dependent on VEGF-mediated formation of new blood
vessels [5].
VEGF is a master regulator of both physiologic and pathologic
angiogenesis. VEGF binds to two tyrosine kinase receptors –
VEGFR1 and VEGFR2. VEGFR2 activation promotes endothe-
lial cell growth, survival, and migration, and increases vascular
permeability [6]. VEGFR1 was previously thought to be a non-
signaling ‘‘decoy’’ receptor, but recent studies have demonstrated
its involvement in pathologic angiogenesis [7] and the recruitment
of BMDCs [8], including macrophages and endothelial precursor
cells [9]. Whereas VEGFR2 is primarily expressed by endothelial
cells, VEGFR1 is expressed by multiple cell types, including cells
of the myeloid lineage (e.g., macrophages [7]). These have recently
been recognized as significant contributors to adipose tissue
composition and function [10,11]. Several reports have suggested
that antivascular treatments could reduce body weight in mouse
models of obesity [12,13,14], but whether antiangiogenic therapy
by blockade of VEGFR1 or VEGFR2 can achieve this effect
remains unknown.
Many aspects of neovascularization during diet-induced
adipose tissue expansion remain poorly understood. VEGF is
up-regulated during adipogenesis [15], but there are conflicting
reports regarding both local and systemic VEGF levels during
obesity [16,17,18,19,20]. We have previously shown that de novo
adipogenesis (from transplanted pre-adipocyes) and neovascular-
ization are reciprocally regulated via a VEGFR2-mediated
paracrine mechanism(s) [21]. Whether blocking VEGFR2
during DIO limits fat expansion remains unknown. Other
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studies have reported the involvement of VEGFR1 signaling in
fat tissue formation. For example, mice deficient for placental-
derived growth factor (PlGF, a specific ligand for VEGFR1)
have lower body weights during the later stages of DIO.
However, pharmacologic inhibition of PlGF had no apparent
effect [22]. Here, we show that vasculogenesis is negligible in
DIO, and that VEGFR2 (but not VEGFR1) inhibition can limit
DIO in mice.
Materials and Methods
Animal studies
All procedures were performed according to the Public Health
Service Policy on Humane Care of Laboratory Animals, and
approved by the Massachusetts General Hospital Institutional
Animal Care and Use Committee. Wild-type (WT) C57BL/6J and
FVB mice were bred and maintained in our defined flora facility.
C57BL/6J mice carrying the green fluorescent protein (GFP)
driven by chicken b-actin promoter and cytomegalovirus inter-
mediate early enhancer (Actb-GFP), and FVB mice carrying GFP
driven by the endothelial-specific Tie2 promoter (Tie2-GFP) were
originally purchased from the Jackson Laboratory (Bar Harbor,
ME) and subsequently bred in our facility. Animals were allowed
food and water ad libitum. For DIO experiments, both animals and
food were weighed at regular intervals. Food intake was calculated
from the difference between initial and final food weights, food
spillage was not taken into account.
Reagents and Dosage
Rat anti-mouse monoclonal antibodies against VEGFR1 (MF1)
and VEGFR2 (DC101) were generous gifts from ImClone Systems
Inc. (New York, NY). DC101 was administered i.p. at 40 mg/kg
body weight every 3 days. MF1 was administered i.p. at 500 mg/
mouse every 2 days. 60 kcal% fat diets were purchased from
Research Diets (New Brunswick, NJ).
Bone Marrow Transplantation
Bone marrow transplantation (BMT) was performed after
characterizing the sensitivity of the C57BL/6J and FVB strains
to whole-body irradiation through longitudinal studies. We used
strain-specific lethal doses of radiation to ensure a high degree of
chimerism. Our protocol has been validated in a previous study
[23], where we demonstrated that (i) over 90% of the bone
marrow-derived cells were GFP+ in BMT/Actb-GFP mice; and
(ii) Tie2-GFP is homogeneously expressed by both local derived
and bone marrow derived endothelial cells. Whole-body
irradiation, in a single dose of 9 Gy for FVB mice and 12 Gy
for C57BL/6J mice, was administered to recipient mice. The
recipient mice were salvaged by i.v. injection of 56106 bone
marrow cells harvested from donor mice [23]. Bone marrow
reconstitution was verified by flow cytometric analyses. WT
C57BL/6J receiving transplants from Actb-GFP donors are
referred to as WT/Actb-GFP-BMT, and WT FVB mice
receiving transplants from Tie2-GFP donors are referred to as
WT/Tie2-GFP-BMT.
Immunohistochemistry
Functional (perfused) blood vessels were labeled in anesthetized
mice by i.v. perfusion staining with 0.1 ml of 1 mg/ml biotinylated
Lycopersicon esculentum (Tomato) lectin (Vector Labs, Burlingame,
CA) for 5 minutes [24]. Transcardial perfusion fixation was
subsequently performed using 4% paraformaldehyde. Tissue
samples were excised, dehydrated overnight at 4uC in 30%
sucrose in phosphate buffered saline (PBS), embedded in OCT
compound and stored at 280uC. Tissue sections (20–30 mm thick)
were mounted on slides using Vectashield mounting media for
fluorescence (Vector Labs). Fluorescence counterstaining was
performed using the nuclear dye DAPI (Molecular Probes,
Eugene, OR). Co-localization of GFP+ BMDCs with lectin-stained
capillaries was verified and quantified by confocal microscopy.
The number of GFP+ vessels in sections and in intravital
microscopy images was counted in 6–10 regions of interest and
normalized by the total number of lectin-stained (ex vivo) or
dextran-perfused (in vivo) vessels. For cell size quantification,
inguinal and perigonadal fat pads were excised from DIO mice at
various time points following the initiation of high fat diet, fixed at
4uC overnight in 4% paraformaldehyde, then embedded in
paraffin. 10 mm sections were stained with hematoxylin and eosin,
and imaged with a bright field microscope. Cross-sectional areas of
individual fat cells were quantified using a custom-written
computer macro.
Intravital Microscopy
To visualize adipose tissue vasculature, mammary fat pad
chambers (MFPC, Perentes et al., submitted) were implanted in
WT/Tie2-GFP-BMT in aging (more than 18 months old) mice
(n = 2) and in 20–22 weeks old female mice (fed high fat diet for 6
weeks after BMT, n= 4). In vivo multiphoton laser-scanning
microscopy [25] was used to visualize Tie2-GFP-positive BMDCs
in fat tissue vasculature in BMT recipient mice bearing MFPCs.
Blood flow was visualized by intravenous injections of rhodamine-
dextran MW 2,000,000.
Statistical Analysis
Student’s t-test was used to evaluate statistical significance
(defined as P,0.05).
Results
Marginal contribution of BMDCs to vessels during fat
tissue expansion
We used bone marrow transplantation to measure the
contribution of BMDCs to adipose tissue vessels in mice fed
standard chow. To determine the contribution of BMDCs to fat
tissue vessels, we performed lectin perfusion staining in WT/Actb-
GFP-BMT mice four months post-BMT, and analyzed their
abdominal fat tissue sections by confocal microscopy. We detected
GFP+ bone marrow derived endothelial cells (BMD-EC) lining
lectin-stained vessels on rare occasions (Figure 1). Of interest, in
old (,18 month-old) WT/Tie2-GFP-BMT mice that had gained
weight with age, we detected BMDCs in 8.3361.98% (n= 2) of
the mammary fat pad vasculature (Figure 1). We also evaluated
the contribution of BMDC to the vasculature of rapidly expanding
fat tissue by feeding WT/Tie2-GFP-BMT mice a high fat diet and
comparing with mice on regular diet. Blood vessels were imaged
using intravital multiphoton laser-scanning microscopy, as well as
by confocal microscopy in frozen sections of mammary fat pads at
the end of the experiment. The high fat diet induced a significant
increase in body weight after six weeks (n = 4, body weight
30.563.0 g vs. 20.060.8 g for high fat vs. regular diet-fed mice,
p,0.05). The contribution of BMDCs to mammary fat vessels was
estimated as the number of Tie2-GFP+ cells in functional
(rhodamine-dextran perfused) blood vessels. BMDC contribution
to fat vessels during DIO increased significantly compared to mice
on regular diets, but was minimal (0.80% compared to 0.06%,
p,0.05). Similar results were obtained by confocal microscopy in
frozen fat tissue sections (not shown).
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Fat tissue expansion after DIO is suppressed by antibody
blockade of VEGFR2, but not VEGFR1
To study the role of VEGF receptors in fat tissue expansion
during DIO, we monitored the body weight of high fat diet-fed
mice treated with the VEGFR1-specific antibody MF1, the
VEGFR2-specific antibody DC101 or with PBS, and untreated
controls. The high fat diet induced rapid weight gain in control
mice (Figure 2A), accompanied by a continuous increase in
adipocyte size over the length of the study (Figure 2B). There
was no significant difference in body weight between untreated
animals and animals treated with PBS throughout the course of
the experiment, therefore data from those two groups were
pooled for subsequent analyses (HFD). Antiangiogenic treatment
with DC101 had no significant effect on body weight during the
first 5–6 weeks of DIO. However, after this period the rate of
weight gain in DC101-treated animals decreased significantly
compared to the HFD controls (Figure 2A, DC101+HFD vs.
HFD). This is consistent with our previous finding that VEGF-
VEGFR2 pathway is critical for both angiogenesis and
adipogenesis during de novo adipose tissue formation from
preadipocytes [21]. We did not observe overt signs of toxicity
in any of the experimental groups, similar to a lack of toxicity in
tumor-bearing mice receiving DC101 for up to 75 days [26].
During the period of lower body weight gain, food intake in the
DC101-treated group was significantly lower than in the control
animals (Figure 2C). Therefore, we interrupted treatment to
determine if the effect of DC101 of limiting fat expansion was
reversible. The rate of weight gain resumed at a higher pace
after cessation of anti-VEGFR2 treatment, eventually reaching
the weights of untreated controls (Figure 2D), despite similar
Figure 1. Imaging of adipose tissue vasculature in GFP transgenic mice. A: Incorporation of BMD-EC in mammary fat pad vasculature in WT/
Tie2-GFP-BMT mice. B: Ex vivo confocal microscopy imaging of mammary fat pad in two mice with age-related obesity (,18 months old). BMD-EC
contributed to approximately 8% of the mammary fat pad vasculature. C: Representative image of GFP+ BMD-EC in the mammary fat pad of an obese
mouse after 6 weeks on a high fat diet. BMD-EC contribution to mammary fat pad vasculature was minimal (0.8%, n = 4). Vessels were perfused with
biotinylated-lectin and stained with streptavidin Texas Red (shown in red), while the nuclei were stained with DAPI (in blue, A, B). Rhodamine-dextran
MW 2,000,000 was infused for vessel enhancement in C. D: Representative image of occasional GFP+ BMD-EC (arrow) in perfused mammary fat pad
blood vessels in a 12 months old WT/Actb-GFP-BMT mouse. Vessels were perfused with biotinylated-lectin and stained with streptavidin Texas Red
(red), while the nuclei were stained with DAPI (blue). Images are 1.72 mm across in A, 310 mm across in B, 700 mm across in C, 1.72 mm across in D.
doi:10.1371/journal.pone.0004974.g001
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food intake during DC101 treatment and after cessation of
treatment (2.35 vs 2.29 g/mouse/day).
Discussion
Previous studies have established that fat tissue expansion is
accompanied by an expansion of its supporting network of blood
vessels [5,20]. This expansion is likely driven both by the increased
expression of angiogenic molecules (such as VEGF) during
differentiation of progenitor cells into mature fat cells [15], and
also by the local tissue hypoxia in fat tissue during obesity [27].
Whether the new endothelial cells required for this expansion are
derived from the existing local vasculature, or if they are recruited
from the bone marrow, has not been previously studied. In our
model we found that BMDC contribution to blood vessels in fat
tissue was marginal in mice fed either regular chow or high fat
diet, but appeared increased in the fat tissue of aging mice. These
findings suggest that BMDC contribution to fat tissue blood vessels
likely reflects long-term replenishment by BMDC [28] rather than
active recruitment for vasculogenesis. These data also suggest that
new vessel formation during DIO occurs primarily by angiogenesis
from pre-existing fat vessels.
We found that in mice treated with the VEGFR2-blocking
antibody DC101, there was a significant decrease in food intake
Figure 2. Effects of VEGFR1 and VEGFR2 blockade in mice with DIO. A: Body weight gain relative to weight at day 0 for mice given different
diets and treatments. Male C57BL6 mice, 10–12 weeks old at time 0, were used for all groups. All diets and treatments began at day 0, at dosages and
schedules as described in the Methods section. DC101+HFD: high fat diet, DC101 treatment, white triangles. MF1+HFD: high fat diet, MF1 treatment,
black squares. HFD: high fat diet controls, no treatment (n = 4) or PBS treatment (n = 4), white circles. LFD: standard diet controls, crosses. B: Average
cross-sectional area (mm2) of adipocytes in the perigonadal fat pad at various times after beginning of high fat diet. 3–4 mice at each time point,
.300 adipocytes measured for each mouse. Adipocytes in the inguinal fat pad showed a similar trend (not shown). C: Food intake (g/day/kg body
weight) in the DC101+HFD versus HFD groups, when the DC101+HFD group was gaining less weight (days 43–91). D: Reversibility of the effects of
DC101. DC101 treatment was discontinued from day 91 onward. About two weeks after cessation of treatment, the rate of weight gain in the
previously treated animals resumed at a higher rate, and their body weights eventually caught up with untreated controls. All data reported as
mean6sem. Asterisks denote significant difference between DC101+HFD and HFD groups (P,0.05).
doi:10.1371/journal.pone.0004974.g002
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that coincided with the decrease in body weight gain. The reduced
food intake undoubtedly contributed to the slower weight gain.
However, after cessation of DC101 treatment, the animals
maintained a similar level of reduced food intake, but were
nevertheless able to increase their body weight until it was similar
to that of control animals. This observation suggests that although
food intake in DC101-treated mice was reduced compared to
control mice, change in appetite alone does not completely
account for the reduced body weight gain. We did not investigate
how VEGFR2 blockade changes energy balance. Rather, based
on our previous study showing that VEGFR2 inhibition inhibits de
novo adipogenesis by restricting angiogenesis [21], and studies by
others showing the importance of VEGF and VEGFR2 signaling
in adipose tissue development [5,29,30], we hypothesized that
inhibition of VEGFR2 in adipose tissue may have weight-reducing
effects in diet-induced obesity. The results from our current study
suggest several areas for future investigations, including the
determination of how anti-angiogenic agents (such as DC101)
affect different aspects of energy balance, what biological
mechanism caused the DC101-induced reduction in food intake,
as well as any possible linkage between adipose tissue angiogenesis
and the regulation of appetite.
In this study we did not address the potential effects of VEGFR-
inhibition on endocrine aspects of energy metabolism. However, a
pervious study has reported that VEGF inhibition causes
improved glucose tolerance in mice [31]. The molecular
mechanism responsible for this outcome is unknown. The same
study also showed that VEGF inhibition induced pruning of
capillaries in the fat tissue of the treated mice.
Of interest, the body weight profile of mice with VEGFR2
blockade by DC101 treatment in this study is strikingly similar to
data from mice genetically deficient for PlGF, a selective ligand for
VEGFR1 [22]. In both studies the rate of body weight gain was
initially unaffected by the anti-angiogenic treatment/genetic
modification, then abruptly decreased after about 6 weeks. These
results suggest that blocking angiogenesis may not be effective in
preventing fat tissue growth during early stages of DIO, but may
become important in later stages of expansion.
Anti-VEGFR1 treatment with MF1 had no effect on body
weight throughout two months of treatment (Figure 2A,
MF1+HFD vs. HFD). This finding is also consistent with the
previous report that pharmaceutical neutralization of PlGF did not
inhibit fat expansion in either diet-induced or genetic obesity [22].
As to why genetic deficiency in PlGF gave different results than
pharmaceutical inhibition, one possible reason is difference in
strain background. The PlGF knockout animals used by Linjen et
al were of Swiss and 129SV background, while the animals used
for antibody-blocking experiments in both our current study and
the study by Linjen et al were of C57BL/6J background. Given the
substantial body of literature showing that strain background has
significant impact on metabolic phenotypes, it would not be
surprising if the inhibition of the same genetic pathway could have
divergent results in different strains.
VEGF-A and PlGF play important roles in recruitment of
VEGFR1+ hematopoietic and VEGFR2+ endothelial BMDCs
during new vessel formation in malignant tissues [32]. In our DIO
models, we observed substantial infiltration of BMDCs into fat
tissue (Figure 1D). However, incorporation of these cells into
vessels was minimal, and we did not detect any conversion of
BMDCs into adipocytes. It is likely that most of the BMDCs
observed were infiltrating macrophages, known to accumulate in
large numbers in the fat tissue of obese mice [10,11]. Consistent
with the lack of effect of VEGFR1 inhibition on DIO, we found
that macrophage content in the fat was unchanged in the absence
of VEGFR1 signaling (Tam et al., unpublished data).
Several studies using anti-vascular agents (which induce rapid
endothelial cell death) in obese mice have shown immediate
decreases in body weight [12,13]. This effect is thought to be
caused by damage to the existing blood vessels by induction of
endothelial cell apoptosis. The results of our study suggest that
pharmacologic blockade of VEGFR2—while unable to prevent
DIO or reduce fat content—might be useful in limiting adipose
tissue expansion in DIO. It should also be noted that another study
using the anti-vascular agent TNP-470 in obese mice (both genetic
and diet-induced) showed a slowing of body weight increase
(rather than body weight decrease) that became evident after a
‘‘lag phase’’ of 2–3 weeks following initiation of treatment [14].
Both of these observations were similar to our results with
VEGFR2 inhibition.
Two additional notes of caution are warranted regarding the
implications of the results from our current study. Mammary fat
pads were used in our bone marrow transplantation studies
because they are the only fat tissue that can be observed, with
intact circulation, by intra-vital microscopy. The depot-specific
nature of fat tissue is now well established, and it must be
emphasized that observations made in the mammary fat pad may
not always be applicable to other fat depots. In addition, C57Bl/6J
mice were chosen for the antibody blocking studies because the
C57 strain is an established and well-characterized model of diet-
induced obesity, whereas FVB mice were used in the microscopy
studies because the transgenic mice with GFP expression were
only available on FVB background. There are divergent reports in
the literature regarding the effects of high fat diet on FVB mice –
there are reports that FVB mice are resistant to diet-induced
obesity [33], whereas others report that this strain does develop
diet-induced obesity [34], albeit to a lesser extent than the C57
strain. Our data in FVB mice are consistent with the results by
Martin et al, i.e. the high fat diet-fed FVB mice did develop diet-
induced obesity. Nevertheless, since energy metabolism is known
to be very sensitive to strain background, and results obtained
using one strain generally cannot be assumed to apply to other
strains without some experimental justification.
Several studies in recent years (including one from our
laboratory) have explored the feasibility of fat tissue reduction by
disrupting adipose tissue vasculature [12,13,14,21]. The discovery
that progenitors for white fat cells are derived from the mural cell
compartment of adipose tissue vasculature [35] will undoubtedly
increase interest in this approach. While reduction in body weight
has been achieved in mice after anti-vascular or anti-angiogenic
treatment, some caution is warranted in adapting this to clinical
therapy, since the indiscriminant depletion of overall fat mass may
lead to harmful lipodistrophic effects [36]. Any future therapeutic
approach (such as anti-angiogenic treatments) that seeks to deplete
fat mass must be carefully evaluated for this potential drawback.
Taken together, our results indicate that angiogenesis from local
preexisting vasculature – and not the contribution of BMDCs –
primarily sustains new vessel formation in fat tissue during DIO.
Antiangiogenic treatment by antibody blockade of VEGFR2 but
not of VEGFR1 restricted adipose tissue expansion. These data
provide novel insight for the potential targeting of the fat
vasculature to control DIO.
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